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Mild proteolytic treatment of SW1 116 tumor cells with trypsin or plasmin increases their plasmin-binding ability consid- 
erably by increasing the number of binding sites without altering their affinity. This mechanism may be operative for 
increasing the concentration of active plasmin at the surface of tumor cells. C-terminal lysine residues are involved in 
plasmin binding to cells, since treatment of cells with carboxypeptidase B decreases this binding by 50%. 
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1. INTRODUCTION 
We have previously demonstrated the existence 
on human carcinoma cells of receptors which bind 
plasmin and, with lower affinity, plasminogen [l]. 
These receptors may play an important biological 
role in concentrating plasmin at the surface of 
tumor cells and allowing this enzyme to degrade 
components of the extracellular matrix, thus 
facilitating the progression of tumor cells. 
In the course of these in vitro experiments, we 
generally used aprotinin in order to prevent 
autodegradation of plasmin incubated with the 
tumor cells. Aprotinin did not inhibit plasmin 
binding, showing that the active site of the enzyme 
is not involved in cell binding. In some ex- 
periments, we studied the influence of aprotinin on 
the inhibition of radiolabelled plasmin binding by 
unlabelled plasmin. Surprisingly, in the absence of 
aprotinin, unlabelled plasmin did not inhibit, but, 
rather, increased the binding of radiolabelled 
plasmin. This led us to investigate how mild pro- 
teolytic treatment of the tumor cells could modify 
their ability to bind radiolabelled plasmin. 
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2. MATERIALS AND METHODS 
The tumor cell line SW1 116 (originating from a human col- 
onic carcinoma) was used in all experiments. Cells were grown 
in MacCoy’s medium supplemented with 10% fetal calf serum, 
then adapted to a defined medium, i.e. MacCoy’s medium 
enriched with insulin (4 fig/ml), transferrin (3 rg/ml) and 
sodium selenite (10 ng/ml), all purchased from Sigma (St. 
Louis, MO) and EGF (5 ng/ml) from Collaborative Research 
(Lexington, MA). After trypsinization, tumor cells were seeded 
in individual plastic microwells (Remova wells, Bioblock, 
Strasbourg) at a rate of 10s cells per well. They were able to at- 
tach and to grow in the same defined medium and reached their 
initial number at day 5. 
Plasminogen and plasmin were purchased from Kabi 
(Stockholm), trypsin (type IX) from Sigma and DFP-treated 
carboxypeptidase B from porcine pancreas from Boehringer 
(Mannheim). Plasminogen was labelled with i2sI (Amersham, 
Les Ulis, France), using the iodogen technique [2]. A specific 
activity of 6-8 &i/,ug (222-296 kBq) was achieved. 10 fig 
radiolabelled plasminogen were transformed into plasmin by 
the addition of 1000 IU urokinase (Choay, Paris). Completion 
of this activation was checked by polyacrylamide gel elec- 
trophoresis followed by autoradiography. 
Plasmin (or plasminogen) binding by tumor cells was per- 
formed as in [l]. Briefly, tumor cells in each well were in- 
cubated with 100~1 of 20 nM labelled plasmin for 30 min at 
4”C, then washed, and the binding determined in a gamma 
spectrometer (Wallac, Finland). In parallel experiments, 20 nM 
labelled plasmin was mixed with various concentrations of 
unlabelled plasmin (20 nM-1 FM) in order to yield an inhibi- 
tion curve. Binding and inhibition experiments were performed 
in the presence (100 KIU) or absence (in some cases) of 
aprotinin (Trasylol, Sigma). 
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In other experiments, tumor cells were pretreated with an en- 
zyme under various conditions, then washed and incubated with 
radiolabelled plasmin. The various conditions included: 
pretreatment with 20 nM unlabelled plasmin for 30 min at 4°C; 
pretreatment with various concentrations of plasmin 
(0.66-66 nM) or trypsin (I-100 U/ml) for 10 min at 37°C; 
pretreatment with DFP-treated carboxypeptidase (0.2-20 
U/ml) for 10 min at 37°C; pretreatment with fixed concentra- 
tions of enzyme for various times (5-60 min) at 37°C. 
In all these experiments aprotinin was omitted during 
pretreatment and added to radiolabelled plasmin. 
Scatchard plots were established from inhibition curves, 
using a program that allowed calculation of the binding 
parameters, dissociation constant and number of binding sites. 
This allowed the comparison of inhibition curves obtained with 
or without proteolytic pretreatment. 
Gel electrophoresis was performed in 10% acrylamide in the 
presence of 0.1% SDS and 0.2 mM mercaptoethanol. Gels were 
dried and covered with Hyper films MP (Amersham), the ex- 
posure time varying from 6 to 24 h. 
3. RESULTS 
3.1. Comparison of inhibition curves of plasmin 
binding 
In the presence of aprotinin, a typical inhibition 
curve was obtained using increasing concentrations 
of unlabelled plasmin. In contrast, when aprotinin 
was omitted, low doses of unlabelled plasmin in- 
creased the binding of radiolabelled plasmin con- 
siderably (fig.1). This effect decreased at higher 
doses of unlabelled plasmin and was followed by a 
typical inhibition. A similar effect was observed 
when plasminogen was used as ligand, and plasmin 
as competitor. 
3.2. Pretreatment of tumor cells with an enzyme 
When tumor cells were incubated with 20 nM 
unlabelled plasmin, a 2-5-fold increase in plasmin 
binding was always observed in comparison to ex- 
periments where cells were preincubated with PBS. 
This increased plasmin binding was specific, as 
shown by inhibition experiments. For instance, the 
binding of 20 nM radiolabelled plasmin was in- 
hibited to an extent of 70-80% by 1 PM unlabelled 
plasmin, whereas 2 PM unlabelled egg albumin 
gave rise to inhibition of only O-10%. 
When tumor cells were preincubated for 10 min 
at 37OC with various concentrations of plasmin or 
trypsin, the same effect as before was observed 
even for low doses of protease (fig.2); binding in- 
creased progressively until a maximum was attain- 
ed (0.25 nM for plasmin, 20 U/ml trypsin). Much 
higher concentrations of proteases still produced 
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Fig.1. Inhibition of radiolabelled plasmin binding to human 
SW1116 cells by cold plasmin (2 x 10e8 M to low6 M) in the 
presence (A-----A) or in the absence (M ) of aprotinin 
(IOO.KIU). 
the same effect. The stimulating effect on plasmin 
binding was seen after 5 min preincubation time 
and increased until a maximum after 30 min. This 
remained the same after 1 h preincubation with 
0.1 PM plasmin, but decreased with 0.4 PM 
plasmin. 
3.3. Pretreatment with carboxypeptidase B 
When carboxypeptidase B was used for pretreat- 
ment of cells, a clear-cut decrease in plasmin 
binding was observed. This amounted to about 
30% when the concentration of carboxypeptidase 
B was 0.2 U/ml and 50% for higher levels 
(2-20 U/ml). A similar effect was noted when car- 
boxypeptidase B was used after pretreatment of 
cells with plasmin. 
3.4. Comparison of Scatchard plots 
By comparing Scatchard plots derived from in- 
hibition curves of plasmin binding (fig.3) obtained 
after preincubation of tumor cells with plasmin or 
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Fig.2. Increase of plasmin binding after cell pretreatment by 
various concentrations of trypsin (a) or plasmin (b). 
PBS, we were able to demonstrate that proteolytic 
pretreatment did not alter the affinity of plasmin 
for tumor cells (& = 1.5 x lo-’ M after pro- 
teolytic pretreatment vs 1 x lo-’ M in the control 
experiment) but increased the number of binding 
sites strongly (60000 vs 15000/tell). 
3.5. Proteolytic pretreatment 
Proteolytic pretreatment did not change the 
structure of bound radiolabelled plasmin, as 
evaluated by SDS-polyacrylamide gel electro- 
phoresis of the cell eluates. Typical plasmin heavy 
and light chains were seen with or without pro- 
teolytic pretreatment (not shown). 
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Fig.3. Comparison of Scatchard plots obtained in parallel 
experiments after (o--o ) and without (H) proteolytic 
pretreatment. 
3.6. Effect of fibrinogen 
The possible role of fibrinogen as plasmin- 
binding protein on the cell surfaces was ruled out 
in two ways. Anti-fibrinogen serum (Behring) did 
not stain SW1 116 cells as determined using im- 
munofluorescence, nor did it inhibit plasma 
binding to these cells. 
4. DISCUSSION 
We have demonstrated an increase in plasmin 
binding by treatment of tumor cells with a trypsin- 
like proteinase. It is likely that such pretreatment 
unmasks lysine residues which react with lysine- 
binding sites of plasmin. Their involvement is 
based on two facts: plasmin binding by tumor cells 
is inhibited strongly by lysine (not shown) and par- 
tially by carboxypeptidase B, which is known to 
cleave off C-terminal lysine and arginine residues 
[3]. This effect of plasmin may play an important 
role in tumor invasion and metastasis. It is likely 
that in vivo tumor cells bind plasminogen and ac- 
tivate it to plasmin through the action of 
23 
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plasminogen activators, especially urokinase. Once 
small amounts of plasmin have been formed, they 
increase the subsequent cell binding of other 
plasminogen and/or plasmin molecules. The final 
concentration of enzyme may thus be strongly in- 
creased, and hence its possible degrading action on 
components of the extracellular matrix. 
Our data are similar to those of Tran-Thang et 
al. [4], who studied the binding of plasminogen to 
fibrin. In their experiments, pretreatment of fibrin 
with a low concentration of plasmin increased 
plasminogen binding several fold, by generating 
high-affinity binding sites reacting with the lysine- 
binding sites of plasminogen. Furthermore, 
Christensen [5] showed that a similar effect on 
fibrinogen molecules due to plasmin treatment was 
suppressed by the addition of carboxypeptidase B. 
These results proved that C-terminal lysine 
residues of proteolytically degraded fibrinogen 
were essential for binding to plasminogen. In our 
system, carboxypeptidase B reduced, but did not 
suppress plasmin binding by tumor cells, showing 
that not all C-terminal lysine residues of plasmin- 
binding molecules are susceptible to treatment with 
this enzyme. Furthermore, plasmin-binding 
molecules present on tumor cells are different from 
fibrinogen, as proved by our negative data with 
anti-fibrinogen serum. 
The plasmin receptor studied here seems dif- 
ferent from those found by another group on 
platelets [6] and on cells of the U937 monocytic cell 
line [7], since these receptors have the same affinity 
(& = 1 PM) for plasminogen and plasmin. 
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